Status:

NOT_YET_RECRUITING

A Prospective Evaluation of a Prescription Digital Therapeutic for Treatment of Overactive Bladder in Women: The RiSolve Trial

Lead Sponsor:

University of Galway

Collaborating Sponsors:

Enterprise Ireland

Conditions:

Overactive Bladder (OAB)

Over Active Bladder

Eligibility:

FEMALE

18+ years

Phase:

NA

Brief Summary

The RiSolve Trial is a prospective, single-arm, post-market clinical investigation designed to evaluate the effectiveness, usability, and safety of a prescription digital therapeutic (PDTx) for women ...

Eligibility Criteria

Inclusion

  • Adult women aged 18 and older with bothersome OAB symptoms: (i.e. must answer YES to one of the following):
  • Do you have a sudden need to rush to the toilet to urinate that is bothersome? OR
  • Does urine leak before you can get to the toilet?
  • Fluency and literacy in English to enable them to understand and complete treatment and required assessments
  • Currently based in the Republic of Ireland
  • Ownership and use of a smartphone
  • Use of at least one mobile App
  • Willing to forego commencing any other OAB treatments outside of RiSolve for the trial treatment period.

Exclusion

  • Current use of an anticholinergic/beta-agonist, within the previous two weeks and/or at the date of consenting
  • Currently using intermittent or indwelling catheter
  • Currently pregnant or planning pregnancy during the study treatment period
  • Currently receiving treatment for bladder/urethral, colon/anal, or cervical cancer
  • Voiding dysfunction (i.e. if Yes is an answer to any of the following):
  • Do you have pain in your bladder? OR
  • Do you have to strain to urinate?
  • Currently using sacral or tibial neuromodulation.
  • Has had intradetrusor therapy
  • Currently taking antibiotics/drugs for urinary tract infection
  • Planning surgery for pelvic organ prolapse within the trial treatment period
  • Planning to undergo pessary fitting during the study period (Note: patients with an existing pessary are eligible) within the trial treatment period
  • Visual impairment such that in the opinion of the PI would impair their use of the app

Key Trial Info

Start Date :

September 29 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 31 2025

Estimated Enrollment :

45 Patients enrolled

Trial Details

Trial ID

NCT07206446

Start Date

September 29 2025

End Date

December 31 2025

Last Update

October 3 2025

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.

A Prospective Evaluation of a Prescription Digital Therapeutic for Treatment of Overactive Bladder in Women: The RiSolve Trial | DecenTrialz